• Patients who have asthma, aspirin-induced allergy, and nasal polyps are at increased risk for developing hypersensitivity reactions. Assess for rhinitis, wheezing, and urticaria.

• Assess for rash periodically during therapy. May cause Stevens-Johnson syndrome or toxic epidermal necrolysis. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.

• Assess pain and range of motion prior to and 1 hr following administration.

• Assess pain (note type, location, and intensity) prior to and 1 hr following administration.

• Monitor temperature; note signs associated with fever (diaphoresis, tachycardia, malaise).

• Evaluate BUN, serum creatinine, CBC, and liver function tests periodically in patients receiving prolonged therapy.

» Serum potassium, BUN, serum creatinine, alkaline phosphatase, LDH, AST, and ALT tests may show ↑ levels. Blood glucose, hemoglobin and hematocrit concentrations, leukocyte and platelet counts, and CCr may be ↓.

» May prolong bleeding time by 3–4 min.

» May alter results of urine albumin, bilirubin, 17-ketosteroid, and 17-hydroxycorticosteroid determinations.